Alzheimer’s disease (AD) is the most common type of dementia characterized by the abnormal accumulation of amyloid-β (Aβ) in the brain. Aβ misfolding is associated with neuroinflammation and synaptic dysfunction, leading to learning and memory deficits. Therefore, Aβ production and aggregation have been one of the most popular drug targets for AD. Failures of drug candidates regulating the aforementioned Aβ cascade stimulated development of immunotherapy agents for clearance of accumulated Aβ in the brain. Here, we report that quinacrine, a blood–brain barrier penetrating antimalarial chemical drug, dissociates Aβ plaques in the brain of AD transgenic mice. When co-incubated with pre-formed Aβ fibrils, quinacrine decreased thioflavin T-positive β-sheets in vitro, on top of its inhibitory function on the fibril formation. We confirmed that quinacrine induced dissociation of high-molecular-weight Aβ aggregates into low-molecular-weight species by dot blots in association with size cut-off filtrations. Quinacrine was then administered to adult 5XFAD transgenic mice via weekly intravenous injections for 6 weeks, and we found a significant reduction of Aβ plaques and astrocytosis in their cortex and hippocampus. In western blots of quinacrine-administered mouse brains, amelioration of AD-related biomarkers, glial fibrillary acidic protein, postsynaptic protein 95, phosphorylated cAMP response element-binding protein, phosphorylated c-Jun N-terminal kinase were observed. Lastly, quinacrine-stimulated dissociation of misfolded aggregates induced recovery of synaptic function associated with Aβ in excitatory post-synaptic current recordings of primary rat cortical neurons treated with Aβ aggregates and quinacrine. Collectively, quinacrine can directly dissociate Aβ fibrils and alleviate decreased synaptic functions.
|Publication status||Published - 2021 Dec|
Bibliographical noteFunding Information:
All images are created by the authors of this manuscript, and all experimental protocols including animal tests in the article were approved by Yonsei University. This work was supported by Korea Health Industry Development Institute (KHIDI) under HU21C0161, National Research Foundation of Korea (NRF) under NRF‐2018R1A6A1A03023718, NRF‐2018R1D1A1B07048857, NRF‐2018M3C7A1021858, and NRF-2021R1A2C1013247, POSCO TJ Foundation under POSCO Science Fellowship, Amyloid Solution, Korea Institute of Toxicology (KK-2011-01), Yonsei University Research Fund (Post Doc. Researcher Supporting Program, 2020-12-0028). Authors appreciate Donghee Lee and Eun Yi Kim for their help in revising the manuscript.
© 2021, The Author(s).
All Science Journal Classification (ASJC) codes